Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pamidronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 19/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.71 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamidronic Acid SCHEMBL2641229 | 0.98 | FDPS (0.68) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL11106361 | 0.96 | FDPS (0.71) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL429804 | 0.88 | FDPS (0.79) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL570526 | 0.87 | FDPS (0.78) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL11037738 | 0.86 | FDPS (0.61) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7831396 | 0.86 | FDPS (0.76) | FDPSPDE3ALMNAADRB3PDE4D | |
| Neridronic Acid SCHEMBL10607521 | 0.84 | FDPS (0.75) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL18361 | 0.84 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5608575 | 0.83 | FDPS (0.73) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL18751 | 0.82 | FDPS (0.64) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7479521-B2 | Tris(hydroxymethyl) acrylamidomethane polymer, inverse latex and microlatex containing same, use of said polymer, inverse latex and microlatex | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES (SEPPIC) (FR) | 2009-01-20 | — | — | US | claimed |
| US-20050014893-A1 | Tris(hydroxymethyl) acrylamidomethane polmer, inverse latex and microlatex containing same, use of said polymer, inverse latex and microlatex | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES (SEPPIC) (FR) | 2005-01-20 | — | — | US | claimed |
| EP-0421921-B1 | Double coated granules | CIBA GEIGY AG (CH) | 1994-04-27 | — | — | EP | claimed |
| US-5096717-A | Disodium 3-amino-1-hydroxypropane-1,1-diphosphonate; controlle d release; oral administration; hydrophilic, elastic coating a nd gastric juice-resistant, intestinal juice-soluble coating; granulation and coating | CIBA-GEIGY CORPORATION (US) | 1992-03-17 | — | — | US | claimed |
| EP-0421921-A1 | Double coated granules | CIBA-GEIGY AG (CH) | 1991-04-10 | — | — | EP | claimed |
| EP-0177443-B1 | CRYSTAL MODIFICATION OF DISODIUM-3-AMINO-1-HYDROXY-PROPANE-1,1-DIPHOSPHONATE | CIBA-GEIGY AG (CH) | 1989-10-18 | — | — | EP | claimed |
| US-4711880-A | FOR CALCIUM AND PHOSPHATE METABOLISM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1987-12-08 | — | — | US | claimed |
| US-4639338-A | Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate | CIBA-GEIGY CORPORATION (US) | 1987-01-27 | — | — | US | claimed |
| EP-0177443-A1 | Crystal modification of disodium-3-amino-1-hydroxy-propane-1,1-diphosphonate | CIBA-GEIGY AG (CH) | 1986-04-09 | — | — | EP | claimed |
| JP-3099016-A | — | — | None | — | — | JP | disclosed |
| US-8916536-B2 | Bone-targeting bisphosphonate duplex drugs | SCHOTT HERBERT (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2601202-B1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT HERBERT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-20130237494-A1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT HERBERT (DE) | 2013-09-12 | — | — | US | disclosed |
| EP-2601202-A1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT, Herbert (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-4639338-A | Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate | CIBA-GEIGY CORPORATION (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0177443-A1 | Crystal modification of disodium-3-amino-1-hydroxy-propane-1,1-diphosphonate | CIBA-GEIGY AG (CH) | 1986-04-09 | — | — | EP | disclosed |
| EP-0177443-A1 | Crystal modification of disodium-3-amino-1-hydroxy-propane-1,1-diphosphonate | CIBA-GEIGY AG (CH) | 1986-04-09 | — | — | EP | disclosed |
| US-4578376-A | 6-AMINO-1-HYDROXYHEXANE-1,1-DIPHOSPHONIC ACID; PAGET'S DOSEASE | ISTITUTO GENTILI S.P.A. (IT) | 1986-03-25 | — | — | US | disclosed |
| US-4104366-A | Compositions for preparation of aqueous solutions of low valence 99 technitium salts | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1978-08-01 | — | — | US | disclosed |
| US-4086334-A | A CALCITONIN AND AN ADJUVANT CONTAINING CARBOXY AND/OR PHOSPHONO GROUPS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DT) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237494-A1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | BPGM, MVD, PPIP5K2 | FDPS 384/4885PDE3A 3238/4885LMNA 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.